Replies to post #140568 on Biotech Values

[jq1234]

We just saw 100% SVR[4] rates combining daclatasvir with GS-7977 in GT1.

We also saw viral relapse and breakthrough in some supposedly easier to treat GT2/3 arm. So, there might be something else going there.

[mcbio]

We just saw 100% SVR rates combining daclatasvir with GS-7977 in GT1.

Yeah but, point being, that was at week 4 and as we saw with ABT combo trial, there can be relapse later on.

My opinion, though biased, is there will never be a need for more than two classes of drugs when partnering GS-7977 with the right drug in treatment-naive patients.

So you're saying you only think GS-7977+ one other HCV DAA will be necessary even in absence of ribavirin?

Medivir is in a very good place. They have a late-stage second-generation P.I., GILD has a questionable pipeline (sans GS-7977), and their results in combination with GS-7977 (if positive) will be in null patients which GS-7977/Riba failed miserably.

Glad to see you still on board with Medivir as you have certainly earned your HCV stripes. Keep in mind, too, that Medivir also does have a nuke, in addition to NS5A, although both, especially the NS5A, are at early stage. All that said, Medivir's near-term fortunes will likely ride on what becomes of TMC435. At this valuation, it's a gamble I'm willing to take.